Compare ELUT & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | NEPH |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 39.0M |
| IPO Year | 2020 | 2004 |
| Metric | ELUT | NEPH |
|---|---|---|
| Price | $0.84 | $3.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | ★ 100.2K | 38.4K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 146.77 | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | $12,293,000.00 | ★ $18,789,000.00 |
| Revenue This Year | N/A | $17.81 |
| Revenue Next Year | N/A | $15.90 |
| P/E Ratio | ★ N/A | $29.75 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.50 | $2.66 |
| 52 Week High | $1.39 | $6.42 |
| Indicator | ELUT | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 44.10 |
| Support Level | $0.74 | $3.19 |
| Resistance Level | $0.87 | $3.78 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 65.53 | 69.23 |
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.